Selective immunosuppression with daclizumab in liver transplantation with graft-versus-host disease.
Riñón
M
M
Section of Immunology, Hospital de Cruces, Baracaldo, Vizcaya, Spain.
Maruri
N
N
Arrieta
A
A
Fernández
J R
JR
Ortiz de Urbina
J
J
García Masdevall
M D
MD
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000920:Antibody-Dependent Cell Cytotoxicity; D015703:Antigens, CD / Q000097:blood; D000077561:Daclizumab; D006086:Graft vs Host Disease / Q000188:drug therapy*; D015654:Herpesvirus 6, Human / Q000302:isolation & purification; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008104:Liver Cirrhosis, Alcoholic / Q000601:surgery; D016031:Liver Transplantation / Q000276:immunology*; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000032:analysis; D019349:Roseolovirus Infections / Q000175:diagnosis; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D000077561:Daclizumab